104.3K
XNAS Volume
High vol. this week
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 1,702 | 0 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 1,702 | 86,256 (0%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 4.91 per share. | 03 Mar 2025 | 272 | 25,000 (0%) | 0% | 4.9 | 1,336 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 919 | 25,272 (0%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 919 | 0 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 519 | 0 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 4.91 per share. | 03 Mar 2025 | 154 | 87,805 (0%) | 0% | 4.9 | 756 | Common Stock |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 519 | 87,959 (0%) | 0% | - | Common Stock | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 26,575 | 53,150 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 44,368 | 84,554 (0%) | 0% | - | Common Stock | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 3,889 | 3,888 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 13,904 | 27,801 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 4.79 per share. | 20 Jan 2025 | 8,928 | 24,353 (0%) | 0% | 4.8 | 42,765 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 25,312 | 33,281 (0%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 14,908 | 29,815 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 8,427 | 16,850 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 1,977 | 1,978 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 69,421 | 138,842 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 115,388 | 143,925 (0%) | 0% | - | Common Stock | |
| Michael Amoroso | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.67 per share. | 20 Jan 2025 | 36,838 | 107,087 (0%) | 0% | 4.7 | 172,033 | Common Stock |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 8,888 | 8,888 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 37,079 | 74,138 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 4.79 per share. | 20 Jan 2025 | 10,287 | 87,440 (0%) | 0% | 4.8 | 49,275 | Common Stock |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 29,168 | 97,727 (0%) | 0% | - | Common Stock | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 16,219 | 32,438 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 10,449 | 20,894 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| Geno J. Germano | Director | Purchase of securities on an exchange or from another person at price $ 4.49 per share. | 30 Dec 2024 | 3,605 | 7,807 (0%) | 0% | 4.5 | 16,186 | Common Stock |
| John Kelly Alexander | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.75 per share. | 27 Dec 2024 | 2,113 | 40,186 (0%) | 0% | 4.8 | 10,037 | Common Stock |
| J. Kevin Buehler | Director | Purchase of securities on an exchange or from another person at price $ 4.88 per share. | 27 Dec 2024 | 4,320 | 8,712 (0%) | 0% | 4.9 | 21,082 | Common Stock |
| Melinda Brown | Director | Purchase of securities on an exchange or from another person at price $ 4.55 per share. | 26 Dec 2024 | 3,016 | 7,218 (0%) | 0% | 4.6 | 13,723 | Common Stock |
| John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.76 per share. | 21 Nov 2024 | 3,000 | 38,073 (0%) | 0% | 6.8 | 20,280 | Common Stock |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2024 | 3,605 | 3,605 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2024 | 3,605 | 35,073 (0%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2024 | 1,836 | 8,557 (0%) | 0% | 0 | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2024 | 1,836 | 1,835 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 8.19 per share. | 02 Nov 2024 | 588 | 7,969 (0%) | 0% | 8.2 | 4,816 | Common Stock |
| Michael Amoroso | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.19 per share. | 02 Nov 2024 | 3,012 | 28,537 (0%) | 0% | 8.2 | 24,668 | Common Stock |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2024 | 9,443 | 9,444 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2024 | 9,443 | 31,549 (0%) | 0% | - | Common Stock | |
| John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2024 | 79,725 | 79,725 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2024 | 44,723 | 44,723 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2024 | 208,263 | 208,263 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2024 | 48,657 | 48,657 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 454 | 31,468 (0%) | 0% | - | Common Stock | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 454 | 0 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 301 | 6,814 (0%) | 0% | 0 | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 301 | 0 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 11.78 per share. | 07 Jun 2024 | 93 | 6,721 (0%) | 0% | 11.8 | 1,096 | Common Stock |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 163 | 68,609 (0%) | 0% | - | Common Stock | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 163 | 0 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 11.80 per share. | 07 Jun 2024 | 50 | 68,559 (0%) | 0% | 11.8 | 590 | Common Stock |
| Geno J. Germano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 9,826 | 9,826 | - | - | Restricted Stock Units | |
| Kevin J. Buehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 9,826 | 9,826 | - | - | Restricted Stock Units | |
| Samuel C. Wadsworth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 9,826 | 9,826 | - | - | Restricted Stock Units | |
| Melinda Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 9,826 | 9,826 | - | - | Restricted Stock Units | |
| Stanley R. Frankel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 9,826 | 9,826 | - | - | Restricted Stock Units | |
| Shari Lisa Pire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 9,826 | 9,826 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.00 per share. | 08 May 2024 | 8,334 | 31,014 (0%) | 0% | 12 | 100,008 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 12.00 per share. | 08 May 2024 | 833 | 6,513 (0%) | 0% | 12 | 9,996 | Common Stock |
| Michael Amoroso | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 12.00 per share. | 08 May 2024 | 8,334 | 22,106 (0%) | 0% | 12 | 100,008 | Common Stock |
| Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 12.00 per share. | 08 May 2024 | 833 | 68,446 (0%) | 0% | 12 | 9,996 | Common Stock |
| Geno J. Germano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 4,202 (0%) | 0% | - | Common Stock | |
| Geno J. Germano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 0 | - | - | Restricted Stock Units | |
| Kevin J. Buehler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 4,392 (0%) | 0% | - | Common Stock | |
| Kevin J. Buehler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 0 | - | - | Restricted Stock Units | |
| Samuel C. Wadsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 4,202 (0%) | 0% | - | Common Stock | |
| Samuel C. Wadsworth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 0 | - | - | Restricted Stock Units | |
| Melinda Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 4,202 (0%) | 0% | - | Common Stock | |
| Melinda Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 0 | - | - | Restricted Stock Units | |
| Stanley R. Frankel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 0 | - | - | Restricted Stock Units | |
| Stanley R. Frankel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 4,252 (0%) | 0% | - | Common Stock | |
| Shari Lisa Pire | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 4,202 (0%) | 0% | - | Common Stock | |
| Shari Lisa Pire | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 4,202 | 0 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 May 2024 | 918 | 919 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 918 | 5,952 (0%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 10.32 per share. | 01 May 2024 | 272 | 5,680 (0%) | 0% | 10.3 | 2,807 | Common Stock |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 3,417 | 3,417 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.32 per share. | 01 May 2024 | 1,526 | 13,772 (0%) | 0% | 10.3 | 15,748 | Common Stock |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 3,417 | 15,298 (0%) | 0% | - | Common Stock | |
| Alan List | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.32 per share. | 01 May 2024 | 290 | 4,488 (0%) | 0% | 10.3 | 2,993 | Common Stock |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 982 | 981 | - | - | Restricted Stock Units | |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 982 | 4,778 (0%) | 0% | - | Common Stock | |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2024 | 868 | 4,034 (0%) | 0% | - | Common Stock | |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2024 | 868 | 0 | - | - | Restricted Stock Units | |
| Alan List | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.03 per share. | 26 Apr 2024 | 238 | 3,796 (0%) | 0% | 10.0 | 2,386 | Common Stock |
| John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2024 | 41,705 | 41,705 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2024 | 25,277 | 25,277 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2024 | 111,217 | 111,217 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2024 | 31,343 | 31,343 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 1,702 | 1,702 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 18.50 per share. | 29 Feb 2024 | 506 | 20,978 (0%) | 0% | 18.5 | 9,361 | Common Stock |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 1,702 | 22,680 (0%) | 0% | - | Common Stock | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 519 | 519 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 12.42 per share. | 29 Feb 2024 | 1,006 | 67,248 (0%) | 0% | 12.4 | 12,495 | Common Stock |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 519 | 67,767 (0%) | 0% | - | Common Stock | |
| Jeff Smith | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 10.32 per share. | 29 Feb 2024 | 154 | 67,613 (0%) | 0% | 10.3 | 1,589 | Common Stock |
| Scimeca Dario | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 20 Jan 2024 | 21,287 | 151,028 (0%) | 0% | 0.4 | 7,663 | Common Stock |
| Smith Jeff | Chief Research Officer | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 20 Jan 2024 | 28,000 | 1,987,269 (3%) | 0% | 0.4 | 10,360 | Common Stock |
| Amoroso Michael | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 266,720 | 493,823 (0%) | 0% | - | Common Stock | |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 60,012 | 116,508 (0%) | 0% | - | Common Stock | |
| Michael Amoroso | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 20 Jan 2024 | 137,390 | 356,433 (0%) | 0% | 0.4 | 49,460 | Common Stock |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 266,720 | 533,280 | - | - | Restricted Stock Units | |
| Kelly John Alexander | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 116,690 | 233,310 | - | - | Restricted Stock Units | |
| Scimeca Dario | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 59,345 | 118,655 | - | - | Restricted Stock Units | |
| Kelly John Alexander | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 116,690 | 614,169 (1%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 59,345 | 172,315 (0%) | 0% | - | Common Stock | |
| List Alan | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 60,012 | 119,988 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 75,015 | 2,015,269 (3%) | 0% | - | Common Stock | |
| Alan List | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 20 Jan 2024 | 21,526 | 94,982 (0%) | 0% | 0.4 | 7,749 | Common Stock |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 75,015 | 149,985 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.48 per share. | 18 Aug 2023 | 90,000 | 383,340 (0%) | 0% | 0.5 | 43,200 | Common Stock |
| Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 6,060 | 27,502 (0%) | 0% | - | Common Stock | |
| Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 6,060 | 6,060 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 34,091 | 0 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 13,635 | 293,340 (0%) | 0% | - | Common Stock | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 34,091 | 279,705 (0%) | 0% | - | Common Stock | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 13,635 | 13,635 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 22,727 | 0 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 0.75 per share. | 07 Jun 2023 | 13,361 | 68,473 (0%) | 0% | 0.8 | 10,021 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 9,044 | 81,834 (0%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 22,727 | 72,790 (0%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 9,044 | 9,045 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 4,872 | 4,872 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 4,872 | 1,935,079 (3%) | 0% | - | Common Stock | |
| Geno J. Germano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 126,075 | 126,075 | - | - | Restricted Stock Units | |
| Kevin J. Buehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 126,075 | 126,075 | - | - | Restricted Stock Units | |
| Samuel C. Wadsworth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 126,075 | 126,075 | - | - | Restricted Stock Units | |
| Melinda Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 126,075 | 126,075 | - | - | Restricted Stock Units | |
| Stanley R. Frankel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 126,075 | 126,075 | - | - | Restricted Stock Units | |
| Shari Lisa Pire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 126,075 | 126,075 | - | - | Restricted Stock Units | |
| Alan List | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.79 per share. | 26 Apr 2023 | 7,771 | 56,496 (0%) | 0% | 0.8 | 6,139 | Common Stock |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 26,027 | 26,028 | - | - | Restricted Stock Units | |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 26,027 | 64,267 (0%) | 0% | - | Common Stock | |
| Kevin J. Buehler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 5,701 | 5,701 (0%) | 0% | - | Common Stock | |
| Kevin J. Buehler | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2023 | 5,701 | 0 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.82 per share. | 21 Mar 2023 | 46,999 | 68,738 (0%) | 0% | 0.8 | 38,539 | Common Stock |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 102,535 | 115,737 (0%) | 0% | - | Common Stock | |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2023 | 102,535 | 205,009 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.86 per share. | 17 Mar 2023 | 20,000 | 245,614 (0%) | 0% | 0.9 | 17,200 | Common Stock |
| Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 12,722 | 25,439 | - | - | Restricted Stock Units | |
| Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 12,722 | 21,422 (0%) | 0% | - | Common Stock | |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 29,453 | 47,713 (0%) | 0% | - | Common Stock | |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 29,453 | 58,890 | - | - | Restricted Stock Units | |
| Alan List | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 03 Mar 2023 | 9,473 | 38,240 (0%) | 0% | 1.1 | 10,136 | Common Stock |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 51,071 | 225,614 (0%) | 0% | - | Common Stock | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 51,071 | 102,114 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.95 per share. | 28 Feb 2023 | 11,605 | 174,543 (0%) | 0% | 1.0 | 11,025 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 27,558 | 62,235 (0%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 27,558 | 55,101 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 28 Feb 2023 | 12,172 | 50,063 (0%) | 0% | 1.1 | 13,024 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.95 per share. | 28 Feb 2023 | 2,163 | 34,677 (0%) | 0% | 1.0 | 2,055 | Common Stock |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 15,576 | 31,144 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 15,576 | 1,930,207 (3%) | 0% | - | Common Stock | |
| Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.95 per share. | 28 Feb 2023 | 12,157 | 1,914,631 (3%) | 0% | 0.9 | 11,549 | Common Stock |
| Shane Barton | VP & Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 70,000 | 70,000 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 350,000 | 350,000 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 178,000 | 178,000 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 800,000 | 800,000 | - | - | Restricted Stock Units | |
| Alan List | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 180,000 | 180,000 | - | - | Restricted Stock Units | |
| Jeff Smith | Chief Research Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 225,000 | 225,000 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2022 | 165,200 | 165,200 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2022 | 850,000 | 850,000 | - | - | Restricted Stock Units | |
| Alexander John Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2022 | 324,500 | 324,500 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2022 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2022 | 24,208 | 0 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.32 per share. | 15 Oct 2022 | 11,006 | 13,202 (0%) | 0% | 1.3 | 14,528 | Common Stock |
| Michael Amoroso | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2022 | 24,208 | 24,208 (0%) | 0% | - | Common Stock | |
| John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.23 per share. | 22 Sep 2022 | 8,200 | 162,938 (0%) | 0% | 1.2 | 10,086 | Common Stock |
| John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.34 per share. | 22 Sep 2022 | 37,037 | 154,738 (0%) | 0% | 1.3 | 49,630 | Common Stock |
| John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.50 per share. | 22 Jun 2022 | 33,784 | 117,701 (0%) | 0% | 1.5 | 50,676 | Common Stock |
| Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 6,061 | 8,720 (0%) | 0% | - | Common Stock | |
| Shane Barton | VP & Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 6,061 | 12,120 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 13,638 | 83,917 (0%) | 0% | - | Common Stock | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 13,638 | 27,270 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 34,090 | 34,091 | - | - | Restricted Stock Units | |
| John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 34,090 | 70,279 (0%) | 0% | - | Common Stock | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 29,545 | 29,545 | - | - | Restricted Stock Units | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 29,545 | 4,061,824 (7%) | 0% | - | Common Stock | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 12,199 | 4,074,023 (8%) | 0% | - | Common Stock | |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 07 Jun 2022 | 18,849 | 4,055,174 (7%) | 0% | 2.1 | 38,829 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 12,199 | 24,391 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 9,047 | 42,347 (0%) | 0% | - | Common Stock | |
| Dario Scimeca | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 07 Jun 2022 | 9,833 | 32,514 (0%) | 0% | 2.1 | 20,256 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 22,727 | 22,727 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 9,047 | 18,089 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 22,727 | 33,300 (0%) | 0% | - | Common Stock | |
| Melinda Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 376,683 | 376,683 | - | - | Stock Option (Right to Buy) | |
| Geno J. Germano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 156,951 | 156,951 | - | - | Stock Option (Right to Buy) | |
| Raymond F. Schinazi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 156,951 | 156,951 | - | - | Stock Option (Right to Buy) | |
| Kevin J. Buehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 156,951 | 156,951 | - | - | Stock Option (Right to Buy) | |
| Samuel C. Wadsworth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 156,951 | 156,951 | - | - | Stock Option (Right to Buy) | |
| Shari Lisa Pire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 156,951 | 156,951 | - | - | Stock Option (Right to Buy) | |
| Stanley R. Frankel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 156,951 | 156,951 | - | - | Stock Option (Right to Buy) | |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2022 | 26,035 | 26,035 (0%) | 0% | - | Common Stock | |
| Alan List | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2022 | 26,035 | 52,055 | - | - | Restricted Stock Units | |
| Alan List | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.10 per share. | 26 Apr 2022 | 7,775 | 18,260 (0%) | 0% | 2.1 | 16,328 | Common Stock |
| Kevin J. Buehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2022 | 5,701 | 5,701 | - | - | Restricted Stock Units | |
| Kevin J. Buehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2022 | 8,763 | 8,763 | - | - | Stock Option (Right to Buy) | |
| Michael Amoroso | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 307,544 | 307,544 | - | - | Restricted Stock Units | |
| Michael Amoroso | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 482,771 | 482,771 | - | - | Employee Stock Option (Right to Buy) | |
| John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.08 per share. | 17 Mar 2022 | 16,677 | 36,189 (0%) | 0% | 3.1 | 51,365 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 98,401 | 98,401 | - | - | Restricted Stock Units | |
| Derek Jantz | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 156,271 | 156,271 | - | - | Employee Stock Option (Right to Buy) | |
| Alan List | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 140,299 | 140,299 | - | - | Employee Stock Option (Right to Buy) | |
| Alan List | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 88,343 | 88,343 | - | - | Restricted Stock Units | |
| Samuel C. Wadsworth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2021 | 55,360 | 55,360 | - | - | Stock Option (Right to Buy) | |
| Shari Lisa Pire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2021 | 55,360 | 55,360 | - | - | Stock Option (Right to Buy) | |
| David Thomson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2021 | 30,000 | 19,255 | - | - | Employee Stock Option (Right to Buy) | |
| David Thomson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 23 Jun 2021 | 30,000 | 111,513 (0%) | 0% | 10.7 | 319,500 | Common Stock |
| David Thomson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 23 Jun 2021 | 30,000 | 141,513 (0%) | 0% | 1.2 | 35,400 | Common Stock |
| David Thomson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 21 Jun 2021 | 15,000 | 126,513 (0%) | 0% | 1.2 | 17,700 | Common Stock |
| David Thomson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2021 | 15,000 | 49,255 | - | - | Employee Stock Option (Right to Buy) | |
| David Thomson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.77 per share. | 21 Jun 2021 | 15,000 | 111,513 (0%) | 0% | 10.8 | 161,550 | Common Stock |
| David Thomson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.44 per share. | 17 Jun 2021 | 10,000 | 111,513 (0%) | 0% | 10.4 | 104,400 | Common Stock |
| David Thomson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 10,000 | 64,255 | - | - | Employee Stock Option (Right to Buy) | |
| David Thomson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 10,000 | 74,255 | - | - | Employee Stock Option (Right to Buy) | |
| David Thomson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 11.00 per share. | 17 Jun 2021 | 10,000 | 111,513 (0%) | 0% | 11 | 110,000 | Common Stock |
| David Thomson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 17 Jun 2021 | 10,000 | 121,513 (0%) | 0% | 1.2 | 11,800 | Common Stock |
| David Thomson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 17 Jun 2021 | 10,000 | 121,513 (0%) | 0% | 1.2 | 11,800 | Common Stock |
| Shane Barton | VP & Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 31,242 | 31,242 | - | - | Employee Stock Option (Right to Buy) | |
| Shane Barton | VP & Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 18,181 | 18,181 | - | - | Restricted Stock Units | |
| Derek Jantz | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 36,590 | 36,590 | - | - | Restricted Stock Units | |
| Derek Jantz | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 59,090 | 59,090 | - | - | Restricted Stock Units | |
| Derek Jantz | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 101,537 | 101,537 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 62,875 | 62,875 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 1,312 | 1,312 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 763 | 763 | - | - | Restricted Stock Units | |
| Fayaz Khazi | CEO of Elo Life Systems | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 23,999 | 23,999 | - | - | Restricted Stock Units | |
| Fayaz Khazi | CEO of Elo Life Systems | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 41,240 | 41,240 | - | - | Employee Stock Option (Right to Buy) | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 27,136 | 27,136 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 46,629 | 46,629 | - | - | Employee Stock Option (Right to Buy) | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 45,454 | 45,454 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 78,106 | 78,106 | - | - | Employee Stock Option (Right to Buy) | |
| Alan List | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 78,090 | 78,090 | - | - | Restricted Stock Units | |
| Alan List | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 134,186 | 134,186 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.38 per share. | 17 May 2021 | 20,000 | 4,032,279 (7%) | 0% | 9.4 | 187,600 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 14 May 2021 | 21,514 | 4,061,952 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2021 | 21,514 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.17 per share. | 14 May 2021 | 9,673 | 4,052,279 (7%) | 0% | 9.2 | 88,701 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 13 May 2021 | 21,514 | 2,023,272 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2021 | 21,514 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.96 per share. | 13 May 2021 | 9,675 | 2,013,597 (3%) | 0% | 9.0 | 86,688 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 12 May 2021 | 21,514 | 4,050,111 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 12 May 2021 | 21,514 | 4,038,273 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.72 per share. | 12 May 2021 | 9,676 | 4,028,597 (7%) | 0% | 8.7 | 84,375 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2021 | 21,514 | 21,514 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2021 | 21,514 | 43,028 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.15 per share. | 12 May 2021 | 9,673 | 4,040,438 (7%) | 0% | 9.2 | 88,508 | Common Stock |
| Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 32,800 | 32,800 | - | - | Stock Option (Right to Buy) | |
| Geno J. Germano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 32,800 | 32,800 | - | - | Stock Option (Right to Buy) | |
| Raymond F. Schinazi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 32,800 | 32,800 | - | - | Stock Option (Right to Buy) | |
| Kevin J. Buehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 32,800 | 32,800 | - | - | Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 07 May 2021 | 21,514 | 1,999,732 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 21,514 | 21,514 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 21,514 | 43,028 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.25 per share. | 07 May 2021 | 9,746 | 2,001,758 (3%) | 0% | 8.3 | 80,405 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 07 May 2021 | 21,514 | 2,011,504 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 07 May 2021 | 9,742 | 1,989,990 (3%) | 0% | 8.6 | 83,489 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2021 | 13,422 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 21 Apr 2021 | 13,422 | 1,978,218 (3%) | 0% | 1.2 | 15,838 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.69 per share. | 19 Apr 2021 | 9,676 | 4,016,759 (7%) | 0% | 8.7 | 84,084 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 21,514 | 64,542 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 19 Apr 2021 | 21,514 | 4,026,435 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.76 per share. | 15 Apr 2021 | 9,676 | 3,993,082 (7%) | 0% | 8.8 | 84,762 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2021 | 21,514 | 86,056 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2021 | 21,514 | 107,570 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.84 per share. | 15 Apr 2021 | 9,675 | 4,004,921 (7%) | 0% | 8.8 | 85,527 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 15 Apr 2021 | 21,514 | 4,014,596 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 15 Apr 2021 | 21,514 | 4,002,758 (7%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 12 Apr 2021 | 21,514 | 1,974,537 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 12 Apr 2021 | 9,741 | 1,964,796 (3%) | 0% | 8.7 | 84,454 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 21,514 | 64,542 | - | - | Employee Stock Option (Right to Buy) | |
| Stanley R. Frankel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 63,325 | 63,325 | - | - | Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 21,514 | 107,570 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.87 per share. | 08 Apr 2021 | 9,737 | 1,953,023 (3%) | 0% | 8.9 | 86,367 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 08 Apr 2021 | 21,514 | 1,962,760 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 08 Apr 2021 | 21,514 | 1,950,982 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.00 per share. | 08 Apr 2021 | 9,736 | 1,941,246 (3%) | 0% | 9 | 87,624 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 21,514 | 86,056 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.08 per share. | 18 Mar 2021 | 9,665 | 3,981,244 (7%) | 0% | 11.1 | 107,088 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2021 | 21,514 | 129,084 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 18 Mar 2021 | 21,514 | 3,990,909 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.97 per share. | 16 Mar 2021 | 9,661 | 3,957,546 (7%) | 0% | 12.0 | 115,642 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2021 | 21,514 | 150,598 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2021 | 21,514 | 172,112 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.92 per share. | 16 Mar 2021 | 9,665 | 3,969,395 (7%) | 0% | 10.9 | 105,542 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 16 Mar 2021 | 21,514 | 3,979,060 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 16 Mar 2021 | 21,514 | 3,967,207 (7%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.36 per share. | 12 Mar 2021 | 9,712 | 1,929,468 (3%) | 0% | 11.4 | 110,328 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2021 | 21,514 | 129,084 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 12 Mar 2021 | 21,514 | 1,939,180 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.79 per share. | 10 Mar 2021 | 9,710 | 1,905,863 (3%) | 0% | 11.8 | 114,481 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 21,514 | 150,598 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 21,514 | 172,112 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.38 per share. | 10 Mar 2021 | 9,711 | 1,917,666 (3%) | 0% | 11.4 | 110,511 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 10 Mar 2021 | 21,514 | 1,927,377 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 10 Mar 2021 | 21,514 | 1,915,573 (3%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.04 per share. | 22 Feb 2021 | 9,660 | 3,945,693 (7%) | 0% | 12.0 | 116,306 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 21,514 | 193,626 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 22 Feb 2021 | 21,514 | 3,955,353 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.55 per share. | 18 Feb 2021 | 9,663 | 3,933,839 (7%) | 0% | 11.6 | 111,608 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 21,514 | 215,140 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 21,514 | 236,654 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 18 Feb 2021 | 21,514 | 3,943,502 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.20 per share. | 18 Feb 2021 | 6,871 | 3,921,988 (7%) | 0% | 12.2 | 83,826 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 18 Feb 2021 | 21,514 | 3,928,859 (7%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.23 per share. | 18 Feb 2021 | 9,705 | 1,889,446 (3%) | 0% | 12.2 | 118,692 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 18 Feb 2021 | 21,514 | 1,899,151 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 21,514 | 193,626 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.28 per share. | 16 Feb 2021 | 9,705 | 1,877,637 (3%) | 0% | 12.3 | 119,177 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 16 Feb 2021 | 21,514 | 1,887,342 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 16 Feb 2021 | 21,514 | 1,875,525 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.30 per share. | 16 Feb 2021 | 9,697 | 1,865,828 (3%) | 0% | 13.3 | 128,970 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 21,514 | 215,140 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 21,514 | 236,654 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.25 per share. | 29 Jan 2021 | 6,444 | 3,907,345 (7%) | 0% | 12.3 | 78,939 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 21,515 | 258,168 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 29 Jan 2021 | 21,515 | 3,913,789 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.68 per share. | 27 Jan 2021 | 7,048 | 3,877,204 (7%) | 0% | 11.7 | 82,321 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 21,514 | 279,683 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 21,514 | 301,197 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.97 per share. | 27 Jan 2021 | 6,444 | 3,892,274 (7%) | 0% | 12.0 | 77,135 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 27 Jan 2021 | 21,514 | 3,898,718 (7%) | 0% | 0.0 | 861 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 27 Jan 2021 | 21,514 | 3,884,252 (7%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.37 per share. | 26 Jan 2021 | 9,697 | 1,854,011 (3%) | 0% | 13.4 | 129,649 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 21,515 | 258,168 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 26 Jan 2021 | 21,515 | 1,863,708 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 22 Jan 2021 | 21,514 | 1,840,592 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 21,514 | 279,683 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 21,514 | 301,197 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.74 per share. | 22 Jan 2021 | 9,695 | 1,842,193 (3%) | 0% | 13.7 | 133,209 | Common Stock |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.04 per share. | 22 Jan 2021 | 21,514 | 1,851,888 (3%) | 0% | 0.0 | 861 | Common Stock |
| Matthew Kane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.53 per share. | 22 Jan 2021 | 10,218 | 1,830,374 (3%) | 0% | 13.5 | 138,250 | Common Stock |
| David Thomson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 16.49 per share. | 21 Jan 2021 | 10,000 | 109,243 (0%) | 0% | 16.5 | 164,900 | Common Stock |
| Matthew Kane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2020 | 1,743 | 1,743 | - | - | Employee Stock Option (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2020 | 8,783 | 8,785 | - | - | Employee Stock Options (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.20 per share. | 15 Jun 2020 | 8,783 | 144,401 (0%) | 0% | 1.2 | 10,540 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 130,109 | 130,109 | - | - | Employee Stock Option (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 112,141 | 112,141 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 202,391 | 202,391 | - | - | Employee Stock Option (Right to Buy) | |
| Fayaz Khazi | CEO of Elo Life Systems | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 107,391 | 107,391 | - | - | Employee Stock Option (Right to Buy) | |
| David Thomson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 154,891 | 154,891 | - | - | Employee Stock Option (Right to Buy) | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 108,424 | 108,424 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Heery | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 133,206 | 133,206 | - | - | Employee Stock Option (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.20 per share. | 15 May 2020 | 8,783 | 134,740 (0%) | 0% | 1.2 | 10,540 | Common Stock |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 15 May 2020 | 878 | 135,618 (0%) | 0% | 1.2 | 1,036 | Common Stock |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2020 | 8,783 | 17,568 | - | - | Employee Stock Options (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2020 | 878 | 3,514 | - | - | Employee Stock Options (Right to Buy) | |
| Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2020 | 41,038 | 41,038 | - | - | Stock Option (Right to Buy) | |
| Raymond F. Schinazi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2020 | 41,038 | 41,038 | - | - | Stock Option (Right to Buy) | |
| Kevin J. Buehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2020 | 41,038 | 41,038 | - | - | Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 14 Apr 2020 | 4,392 | 3,862,738 (7%) | 0% | 1.2 | 5,183 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2020 | 4,392 | 5,854 | - | - | Employee Stock Option (Right to Buy) | |
| Geno J. Germano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 71,776 | 71,776 | - | - | Stock Option (Right To Buy) | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 82,659 | 82,659 | - | - | Restricted Stock Units | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 4.61 per share. | 28 Feb 2020 | 2,748 | 7,976 (0%) | 0% | 4.6 | 12,668 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 10.68 per share. | 28 Feb 2020 | 548 | 8,524 (0%) | 0% | 10.7 | 5,853 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 3.61 per share. | 28 Feb 2020 | 2,049 | 10,573 (0%) | 0% | 3.6 | 7,397 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2020 | 131,271 | 131,271 | - | - | Employee Stock Option (Right to Buy) | |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 5.61 per share. | 28 Feb 2020 | 2,072 | 2,072 (0%) | 0% | 5.6 | 11,624 | Common Stock |
| Dario Scimeca | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 4.79 per share. | 28 Feb 2020 | 3,156 | 5,228 (0%) | 0% | 4.8 | 15,117 | Common Stock |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2020 | 2,634 | 4,392 | - | - | Employee Stock Option (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2020 | 17,566 | 26,351 | - | - | Employee Stock Options (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 06 Jan 2020 | 2,634 | 123,845 (0%) | 0% | 1.2 | 3,108 | Common Stock |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.20 per share. | 06 Jan 2020 | 17,566 | 121,211 (0%) | 0% | 1.2 | 21,079 | Common Stock |
| Christopher Heery | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 12.09 per share. | 19 Dec 2019 | 250 | 250 (0%) | 0% | 12.1 | 3,023 | Common Stock |
| Christopher Heery | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 12.08 per share. | 19 Dec 2019 | 2,235 | 2,485 (0%) | 0% | 12.1 | 26,999 | Common Stock |
| Kevin J. Buehler | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2019 | 60,776 | 60,776 | - | - | Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2019 | 52,651 | 52,651 | - | - | Employee Stock Option (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2019 | 52,818 | 52,818 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2019 | 262,252 | 262,252 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2019 | 10,000 | 13,422 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew Kane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 23 Sep 2019 | 10,000 | 1,812,427 (3%) | 0% | 1.2 | 11,800 | Common Stock |
| Fayaz Khazi | CEO of Elo Life Systems | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2019 | 28,833 | 28,833 | - | - | Employee Stock Option (Right to Buy) | |
| David Thomson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2019 | 30,922 | 30,922 | - | - | Employee Stock Option (Right to Buy) | |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 10 Sep 2019 | 13,176 | 3,858,346 (7%) | 0% | 1.2 | 15,548 | Common Stock |
| Derek Jantz | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2019 | 13,176 | 10,246 | - | - | Employee Stock Option (Right to Buy) | |
| Dario Scimeca | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jul 2019 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.20 per share. | 10 Jun 2019 | 96,618 | 96,618 (0%) | 0% | 1.2 | 115,942 | Common Stock |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2019 | 7,027 | 7,026 | - | - | Employee Stock Option (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2019 | 96,618 | 43,917 | - | - | Employee Stock Option (Right to Buy) | |
| Abid Ansari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 10 Jun 2019 | 7,027 | 103,645 (0%) | 0% | 1.2 | 8,292 | Common Stock |
| David Thomson | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2019 | 117,113 | 117,113 | - | - | Employee Stock Option (Right to Buy) | |
| David Thomson | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.18 per share. | 10 Jun 2019 | 117,113 | 117,113 (0%) | 0% | 1.2 | 138,193 | Common Stock |
| Tony Yao | None | Purchase of securities on an exchange or from another person at price $ 15.42 per share. | 03 Apr 2019 | 6,487 | 158,003 (0%) | 0% | 15.4 | 100,030 | Common Stock |
| Raymond F. Schinazi | None | 01 Apr 2019 | 36,946 | 36,946 (0%) | 0% | 13.6 | 502,466 | Common Stock | |
| Raymond F. Schinazi | None | 01 Apr 2019 | 56,102 | 93,048 (0%) | 0% | - | Common Stock | ||
| Raymond F. Schinazi | None | 01 Apr 2019 | 119,761 | 0 | - | - | Series B Preferred Stock | ||
| Tony Yao | None | 01 Apr 2019 | 244,572 | 0 | - | - | Series B Preferred Stock | ||
| Tony Yao | None | 01 Apr 2019 | 9,500 | 0 | - | - | Series B Preferred Stock | ||
| Tony Yao | None | 01 Apr 2019 | 9,500 | 0 | - | - | Series B Preferred Stock | ||
| Tony Yao | None | 01 Apr 2019 | 4,450 | 4,450 (0%) | 0% | - | Common Stock | ||
| Tony Yao | None | 01 Apr 2019 | 114,570 | 151,516 (0%) | 0% | - | Common Stock | ||
| Tony Yao | None | 01 Apr 2019 | 36,946 | 36,946 (0%) | 0% | 13.6 | 502,466 | Common Stock | |
| Tony Yao | None | 01 Apr 2019 | 4,450 | 4,450 (0%) | 0% | - | Common Stock | ||
| Raymond F. Schinazi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2019 | 34,544 | 34,544 | - | - | Stock Option (Right to Buy) |